SEVARO

# SEVARO: AI-Powered Virtual Neurology

High-Level Overview

Sevaro is a physician-led virtual neurology company that delivers 24/7 telestroke and comprehensive neurological care to hospitals and health systems through its proprietary Synapse AI platform.[1][2] Founded in 2019, the company specializes exclusively in teleneurology rather than attempting to serve multiple medical specialties, positioning itself as a "Master of One" in virtual neurology.[2] Sevaro solves a critical healthcare problem: many hospitals lack adequate onsite vascular neurologists to treat acute stroke patients, where every second determines whether a patient receives life-saving treatment or faces permanent disability or death.[3]

The company serves hospital systems and health networks seeking to improve stroke care outcomes and expand neurological services without maintaining large in-house neurology teams. Sevaro has demonstrated significant growth momentum, raising $11M in Series A funding in February 2023, followed by additional Series B rounds totaling $39M in mid-to-late 2025.[4][6] Its core innovation—connecting patients to vascular neurologists in under 45 seconds through its OneCall technology—has reduced average time-to-treatment for tPA (tissue plasminogen activator) from 46 minutes to 23 minutes, directly improving patient survival rates.[3]

Origin Story

Sevaro was founded in 2019 by Rajiv Narula, a vascular neurologist, establishing the company with deep clinical expertise from the outset.[4] The company emerged from a fundamental frustration with existing telemedicine models: traditional telestroke services operated through standard call centers where messages passed between emergency rooms and neurologists, creating dangerous delays in acute care.[3] Narula and his physician-led team recognized that every second matters in stroke treatment and built Sevaro specifically to eliminate these communication bottlenecks.

The founding team brought extensive real-world experience—employees at Sevaro have collectively worked at over 100 hospitals in dedicated stroke care environments.[3] This clinical pedigree shaped the company's philosophy: solutions designed by physicians, for physicians, with genuine understanding of hospital workflows and patient care pressures. The company's name itself derives from Sanskrit words meaning "selfless service," reflecting its mission-driven orientation.[3]

Core Differentiators

• Physician-Led Architecture: Founded and led by vascular neurologists rather than technologists or business operators, ensuring clinical credibility and deep understanding of neurological care workflows.[3]

• Proprietary OneCall Technology: Connects hospitals to dedicated vascular neurologists in under 45 seconds—dramatically faster than industry-standard call center models that previously took 20+ minutes.[3][5]

• Focused Specialization: Unlike telemedicine competitors offering services across countless specialties, Sevaro concentrates exclusively on virtual neurology, enabling unmatched depth and precision.[2]

• Synapse AI Platform: An advanced human-AI integration system that enhances clinical decision-making, streamlines workflows, and coordinates care across the entire neurological journey—from acute telestroke to neuro-rehabilitation to outpatient follow-up.[2][5]

• Proven Clinical Outcomes: Documented reduction in time-to-treatment for stroke patients (46 minutes to 23 minutes), directly translating to better patient outcomes and reduced disability rates.[3]

• Comprehensive Service Suite: Offers 24/7 telestroke care, neurohospitalist services, remote EEG interpretation, and inpatient neuro-care coordination—creating a complete virtual neurology ecosystem.[1][2]

Role in the Broader Tech Landscape

Sevaro operates at the intersection of three powerful healthcare trends: the telemedicine acceleration, the AI-augmented clinical care movement, and the rural healthcare access crisis. The company addresses a structural problem in American healthcare—geographic maldistribution of neurological expertise—that has only become more acute as stroke incidence remains a leading cause of disability.

The timing is particularly favorable. Hospitals face mounting pressure to improve stroke outcomes (measured by national quality metrics), reduce liability exposure, and expand services without proportional cost increases. Sevaro's model enables hospitals to achieve all three simultaneously. Additionally, the regulatory environment has become increasingly supportive of telehealth, while AI adoption in clinical settings has moved from experimental to expected.[2]

Sevaro's influence extends beyond its direct customers. By demonstrating that focused, physician-led telemedicine can outperform generalist competitors on clinical outcomes, the company influences how healthcare systems evaluate virtual care partnerships. Its emphasis on speed and precision—rather than breadth of services—challenges the prevailing "one-stop-shop" telemedicine model and suggests that specialization may be the competitive advantage in healthcare technology.

Quick Take & Future Outlook

Sevaro is positioned to become the dominant virtual neurology platform in North America. The company's recent $39M Series B funding round signals investor confidence in its clinical model and market opportunity.[6] Key trends shaping its trajectory include: continued consolidation among hospital systems seeking integrated neurology solutions, growing adoption of AI-assisted clinical workflows, and increasing regulatory recognition of telemedicine's role in addressing healthcare disparities.

The company's next phase likely involves geographic expansion (building virtual neurology networks across more hospital systems), deepening its AI capabilities through Synapse AI, and potentially expanding into adjacent neurological subspecialties while maintaining its specialization focus. Its non-profit arm, StatSeva, also positions Sevaro as a player in global health innovation, extending its influence beyond U.S. markets.

What makes Sevaro compelling is that it solves a problem where speed directly saves lives—and it has the clinical credibility and technology to prove it works. In an era of healthcare fragmentation, a physician-led company that refuses to be a "jack of all trades" may be exactly what the market needs.